Top

Published in:

01-12-2014 | Research Article

Promoter polymorphisms of miR-34b/c are associated with risk of gastric cancer in a Chinese population

Authors: Chao Yang, Xiang Ma, Dongxiao Liu, Younan Wang, Ran Tang, Yi Zhu, Zekuan Xu, Li Yang

Published in: Tumor Biology | Issue 12/2014

Abstract

More and more evidence reveals that noncoding RNA miR-34b/c and tumor suppressor gene TP-53 independently, and/or jointly, play crucial roles in carcinogenesis. The purpose of the present hospital-based case–control study was to investigate the association between the miR-34b/c rs4938723 and TP53 Arg72Pro polymorphisms and the risk of gastric cancer. Two polymorphisms were genotyped in 419 gastric cancer patients and 402 age- and sex-matched cancer-free controls using polymerase chain reaction-restriction fragment length polymorphism analysis. The CC genotype and C allele of the miR-34b/c rs4938723 were associated with a significantly decreased risk of gastric cancer compared with the TT genotype and T allele (CC vs. TT: P = 0.006, adjusted odds ratio (OR) = 0.53, 95 % confidence interval (95 % CI) = 0.34–0.83; C vs. T: P = 0.005, adjusted OR = 0.75, 95 % CI = 0.61–0.92). Compared with individuals with the wild-type TT genotype, subjects with the variant genotypes (CT + CC) had a significantly decreased risk of gastric cancer (P = 0.047, adjusted OR = 0.75, 95 % CI = 0.57–0.99). Stratified analysis showed that the association between the risk of gastric cancer and the variant genotypes of miR-34b/c was more profound among men. However, no overall association was found between the TP53 Arg72Pro polymorphism and gastric cancer risk. In the combined analysis, no effects of the interaction of miR-34b/c rs4938723 and TP53Arg72Pro on gastric cancer risk were observed. Our findings indicate that the miR-34b/c rs4938723 CT/CC genotypes may be associated with a decreased risk of gastric cancer and the C allele may be a protective factor in gastric cancer.

Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol. 2006;12(3):354–62.CrossRef

Ushijima T, Sasako M. Focus on gastric cancer. Cancer Cell. 2004;5(2):121–5.CrossRef

Correa P. Human gastric carcinogenesis: a multistep and multifactorial process—first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res. 1992;52(24):6735–40.PubMed

Wu MS, Chen CJ, Lin JT. Host-environment interactions: their impact on progression from gastric inflammation to carcinogenesis and on development of new approaches to prevent and treat gastric cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(8):1878–82. doi:10.1158/1055-9965.EPI-04-0792.CrossRef

Zhu H, Yang L, Zhou B, Yu R, Tang N, Wang B. Myeloperoxidase G-463A polymorphism and the risk of gastric cancer: a case–control study. Carcinogenesis. 2006;27(12):2491–6. doi:10.1093/carcin/bgl121.CrossRef

Gu H, Yang L, Tang N, Zhou B, Zhu H, Sun Q, et al. Association of endothelin-converting enzyme-1b C-338A polymorphism with gastric cancer risk: a case–control study. Eur J Cancer. 2008;44(9):1253–8. doi:10.1016/j.ejca.2007.09.013.CrossRef

Yang L, Gu HJ, Zhu HJ, Sun QM, Cong RH, Zhou B, et al. Tissue inhibitor of metalloproteinase-2 G-418C polymorphism is associated with an increased risk of gastric cancer in a Chinese population. Eur J Surg Oncol. 2008;34(6):636–41. doi:10.1016/j.ejso.2007.09.003.CrossRef

Rozan LM, El-Deiry WS. p53 downstream target genes and tumor suppression: a classical view in evolution. Cell Death Differ. 2007;14(1):3–9. doi:10.1038/sj.cdd.4402058.CrossRef

Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358(6381):15–6.CrossRef

10.

Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R, et al. Mutations and polymorphisms in TP53 gene—an overview on the role in colorectal cancer. Mutagenesis. 2012;27(2):211–8. doi:10.1093/mutage/ger067.CrossRef

11.

Ara S, Lee PS, Hansen MF, Saya H. Codon 72 polymorphism of the TP53 gene. Nucleic Acids Res. 1990;18(16):4961.CrossRef

12.

Hadhri-Guiga B, Toumi N, Khabir A, Sellami-Boudawara T, Ghorbel A, Daoud J, et al. Proline homozygosity in codon 72 of TP53 is a factor of susceptibility to nasopharyngeal carcinoma in Tunisia. Cancer Genet Cytogenet. 2007;178(2):89–93. doi:10.1016/j.cancergencyto.2007.05.013.CrossRef

13.

Jiang P, Liu J, Zeng X, Li W, Tang J. Association of TP53 codon 72 polymorphism with cervical cancer risk in Chinese women. Cancer Genet Cytogenet. 2010;197(2):174–8. doi:10.1016/j.cancergencyto.2009.11.011.CrossRef

14.

Gao LB, Li LJ, Pan XM, Li ZH, Liang WB, Bai P, et al. A genetic variant in the promoter region of miR-34b/c is associated with a reduced risk of colorectal cancer. Biol Chem. 2013;394(3):415–20. doi:10.1515/hsz-2012-0297/j/bchm.2013.394.issue-3/hsz-2012-0297/hsz-2012-0297.xml.CrossRef

15.

Denisov EV, Cherdyntseva NV, Litvyakov NV, Slonimskaya EM, Malinovskaya EA, Voevoda MI, et al. TP53 mutations and Arg72Pro polymorphism in breast cancers. Cancer Genet Cytogenet. 2009;192(2):93–5. doi:10.1016/j.cancergencyto.2009.03.014.CrossRef

16.

Fernandez-Rubio A, Lopez-Cima MF, Gonzalez-Arriaga P, Garcia-Castro L, Pascual T, Marron MG, et al. The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain. Lung Cancer. 2008;61(3):309–16. doi:10.1016/j.lungcan.2008.01.017.CrossRef

17.

Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26(5):745–52. doi:10.1016/j.molcel.2007.05.010.CrossRef

18.

He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature. 2007;447(7148):1130–4. doi:10.1038/nature05939.CrossRef

19.

Xu Y, Liu L, Liu J, Zhang Y, Zhu J, Chen J, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with an increased risk for primary hepatocellular carcinoma. Int J Cancer. 2011;128(2):412–7. doi:10.1002/ijc.25342.CrossRef

20.

Bossard P, Zaret KS. GATA transcription factors as potentiators of gut endoderm differentiation. Development. 1998;125(24):4909–17.CrossRef

21.

Chou J, Provot S, Werb Z. GATA3 in development and cancer differentiation: cells GATA have it! J Cell Physiol. 2010;222(1):42–9. doi:10.1002/jcp.21943.CrossRef

22.

Son MS, Jang MJ, Jeon YJ, Kim WH, Kwon CI, Ko KH, et al. Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma. Gene. 2013;524(2):156–60. doi:10.1016/j.gene.2013.04.042.CrossRef

23.

Zhang S, Qian J, Cao Q, Li P, Wang M, Wang J, et al. A potentially functional polymorphism in the promoter region of miR-34b/c is associated with renal cell cancer risk in a Chinese population. Mutagenesis. 2014;29(2):149–54. doi:10.1093/mutage/geu001.CrossRef

24.

Li L, Sima X, Bai P, Zhang L, Sun H, Liang W, et al. Interactions of miR-34b/c and TP53 polymorphisms on the risk of intracranial aneurysm. Clin Dev Immunol. 2012;2012:567586. doi:10.1155/2012/567586.PubMedPubMedCentral

25.

Li L, Wu J, Sima X, Bai P, Deng W, Deng X, et al. Interactions of miR-34b/c and TP-53 polymorphisms on the risk of nasopharyngeal carcinoma. Tumour Biol. 2013;34(3):1919–23. doi:10.1007/s13277-013-0736-9.CrossRef

26.

Wei YG, Liu F, Li B, Chen X, Ma Y, Yan LN, et al. Interleukin-10 gene polymorphisms and hepatocellular carcinoma susceptibility: a meta-analysis. World J Gastroenterol. 2011;17(34):3941–7. doi:10.3748/wjg.v17.i34.3941.CrossRef

27.

Zhang YM, Zhou XC, Xu Z, Tang CJ. Meta-analysis of epidemiological studies of association of two polymorphisms in the interleukin-10 gene promoter and colorectal cancer risk. Genet Mol Res. 2012;11(3):3389–97. doi:10.4238/2012.September.25.7.CrossRef

28.

Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, et al. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ. 2010;17(2):236–45. doi:10.1038/cdd.2009.109.CrossRef

29.

Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 2010;17(2):193–9. doi:10.1038/cdd.2009.56.CrossRef

30.

Kim NH, Kim HS, Kim NG, Lee I, Choi HS, Li XY, et al. p53 and microRNA-34 are suppressors of canonical Wnt signaling. Sci Signal. 2011;4(197):ra71. doi:10.1126/scisignal.2001744.CrossRef

31.

Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci U S A. 2007;104(39):15472–7. doi:10.1073/pnas.0707351104.CrossRef

32.

Suzuki R, Yamamoto E, Nojima M, Maruyama R, Yamano HO, Yoshikawa K, et al. Aberrant methylation of microRNA-34b/c is a predictive marker of metachronous gastric cancer risk. J Gastroenterol. 2013. doi:https://doi.org/10.1007/s00535-013-0861-7.CrossRefPubMedPubMedCentral

33.

Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008;68(11):4123–32. doi:10.1158/0008-5472.CAN-08-0325.CrossRef

34.

Song HR, Kweon SS, Kim HN, Piao JM, Yun WJ, Choi JS, et al. p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population. Gastric Cancer. 2011;14(3):242–8. doi:10.1007/s10120-011-0034-4.CrossRef

35.

Shen H, Solari A, Wang X, Zhang Z, Xu Y, Wang L, et al. P53 codon 72 polymorphism and risk of gastric cancer in a Chinese population. Oncol Rep. 2004;11(5):1115–20.

36.

Sul J, Yu GP, Lu QY, Lu ML, Setiawan VW, Wang MR, et al. P53 codon 72 polymorphisms: a case–control study of gastric cancer and potential interactions. Cancer Lett. 2006;238(2):210–23. doi:10.1016/j.canlet.2005.07.004.CrossRef

Title: Promoter polymorphisms of miR-34b/c are associated with risk of gastric cancer in a Chinese population
Authors: Chao Yang
Xiang Ma
Dongxiao Liu
Younan Wang
Ran Tang
Yi Zhu
Zekuan Xu
Li Yang
Publication date: 01-12-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 12/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2574-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2014

Impact of neoadjuvant chemotherapy on lymphocytes and co-inhibitory B7-H4 molecule in gastric cancer: low B7-H4 expression associates with favorable prognosis

Pri-miR-34b/c rs4938723 TC heterozygote is associated with increased cancer risks: evidence from published data

Immunization with a novel chimeric peptide representing B and T cell epitopes from HER2 extracellular domain (HER2 ECD) for breast cancer

The clinical implications of Crk-like adaptor protein expression in papillary thyroid microcarcinoma

Baicalin, a component of Scutellaria baicalensis, alleviates anorexia and inhibits skeletal muscle atrophy in experimental cancer cachexia

CRTC2 and PROM1 expression in non-small cell lung cancer: analysis by Western blot and immunohistochemistry

Keynote webinar | Spotlight on antibody–drug conjugates in cancer